Search Result

Results for "

lactate production

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Lactate Dehydrogenase (16) AIM2 (1) Akt (1) AMPK (2) Antibiotic (4) Apoptosis (18) ATP Synthase (1) Autophagy (1) Bacterial (9) Bcl-2 Family (2) Biochemical Assay Reagents (2) Caspase (3) Drug Intermediate (3) Endogenous Metabolite (3) Environmental Pollutants (1) FOXO (1) Fructose-1,6-bisphosphate aldolase (1) Fungal (1) GLUT (1) Heme Oxygenase (HO) (1) Hexokinase (1) HIF/HIF Prolyl-Hydroxylase (1) Interleukin Related (3) Isotope-Labeled Compounds (2) Keap1-Nrf2 (1) Mitochondrial Metabolism (3) NAMPT (1) NKCC (1) NOD-like Receptor (NLR) (1) PDHK (1) PDK-1 (1) Phosphoglycerate Kinase (PGK) (2) Reactive Oxygen Species (ROS) (10) Reference Standards (3) Sirtuin (3) SOD (1) TNF Receptor (1) Topoisomerase (2) VDAC (1)
By Research Areas:	Cancer (25) Cardiovascular Disease (1) Infection (9) Inflammation/Immunology (5) Metabolic Disease (6) Neurological Disease (4)

By Targets:

Lactate Dehydrogenase (16)

AIM2 (1)

Akt (1)

AMPK (2)

Antibiotic (4)

Apoptosis (18)

ATP Synthase (1)

Autophagy (1)

Bacterial (9)

Bcl-2 Family (2)

Biochemical Assay Reagents (2)

Caspase (3)

Drug Intermediate (3)

Endogenous Metabolite (3)

Environmental Pollutants (1)

FOXO (1)

Fructose-1,6-bisphosphate aldolase (1)

Fungal (1)

GLUT (1)

Heme Oxygenase (HO) (1)

Hexokinase (1)

HIF/HIF Prolyl-Hydroxylase (1)

Interleukin Related (3)

Isotope-Labeled Compounds (2)

Keap1-Nrf2 (1)

Mitochondrial Metabolism (3)

NAMPT (1)

NKCC (1)

NOD-like Receptor (NLR) (1)

PDHK (1)

PDK-1 (1)

Phosphoglycerate Kinase (PGK) (2)

Reactive Oxygen Species (ROS) (10)

Reference Standards (3)

Sirtuin (3)

SOD (1)

TNF Receptor (1)

Topoisomerase (2)

VDAC (1)

By Research Areas:

Cancer (25)

Cardiovascular Disease (1)

Infection (9)

Inflammation/Immunology (5)

Metabolic Disease (6)

Neurological Disease (4)

Inhibitors & Agonists

Screening Libraries

Biochemical Assay Reagents

Natural
Products

Isotope-Labeled Compounds

Targets Recommended: Lactate Dehydrogenase

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-W040233

L-Lactic acid sodium 10+ Cited Publications (S)-2-Hydroxypropanoic acid sodium	Environmental Pollutants Antibiotic Endogenous Metabolite Drug Intermediate Bacterial	Infection Cancer
L-lactate Sodium (Sodium (S)-2-hydroxypropanoate) is a buildiing block which can be used as a precursor for the production of the bioplastic polymer poly-lactic acid. L-Lactic acid Sodium has antiproliferative activity .

HY-Y0445A

Sodium dichloroacetate 25+ Cited Publications	PDK-1 NKCC PDHK Reactive Oxygen Species (ROS) Apoptosis	Cancer
Sodium dichloroacetate is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor. Sodium dichloroacetate also stimulates pyruvate dehydrogenase (PDH) activity and works as a Na ⁺-K ⁺-2Cl ⁻ cotransporter (NKCC) inhibitor. Sodium dichloroacetate prevents the phosphorylation of the E1α subunit of PDC, promoting the entry of pyruvate into the mitochondria for oxidative metabolism, reducing lactate production, and simultaneously increasing the production of reactive oxygen species (ROS). Sodium dichloroacetate inhibits tumor cell proliferation and induces apoptosis. Sodium dichloroacetate is promising for research of cancers .

HY-16214

FX-11 25+ Cited Publications LDHA Inhibitor FX11	Lactate Dehydrogenase Apoptosis Reactive Oxygen Species (ROS)	Cancer
FX-11 is a potent, selective, reversible and competitive lactate dehydrogenase A (LDHA) inhibitor, with a K_i of 8 μM. FX-11 reduces ATP levels and induces oxidative stress, ROS production and cell death. FX-11 shows antitumor activity in lymphoma and pancreatic cancer xenografts .

HY-W040118

Galloflavin 10+ Cited Publications	Lactate Dehydrogenase	Cancer
Galloflavin is a potent lactate dehydrogenase (LDH) inhibitor. The calculated K_is for pyruvate are 5.46 μM (LDH-A) and 15.06 μM (LDH-B). Galloflavin hinders the proliferation of cancer cells by blocking glycolysis and ATP production .

HY-N10574

Queuine 1 Publications Verification	Bacterial	Metabolic Disease Cancer
Queuine is a selective substrate for tRNA guanine transglycosylase (TGT) and can be incorporated into eukaryotic tRNA. Queuine promotes tRNA modification, affecting mitochondrial function and Warburg metabolic phenotype. If Queuine is deficient, aerobic glycolysis can be enhanced, oxidative phosphorylation can be inhibited, and Warburg metabolism can be promoted, accompanied by increased ammonia and lactate production and increased lactate dehydrogenase activity. Queuine can be used for autoimmune diseases (such as experimental models of multiple sclerosis) and cancer metabolic regulation, and its deficiency is associated with low tRNA modification in tumor cells .

HY-12203

PFK-158 10+ Cited Publications	Autophagy Apoptosis	Cancer
PFK-158 is a potent and selective PFKFB3 inhibitor with an IC₅₀ value 137 nM. PFK-158 reduces glucose uptake, ATP production, lactate release, and induces apoptosis and autophagy in cancer cells. PFK-158 has broad anti-tumor activity. PFK-158 can also enhance Colistin's resistance to bacteria .

HY-N1511

Ganoderic acid D 2 Publications Verification	Sirtuin Apoptosis	Cancer
Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells . Ganoderic acid D induces HeLa human cervical carcinoma apoptosis .

HY-124113

4'-Bromo-resveratrol 4′‐BR	Sirtuin Apoptosis Caspase Lactate Dehydrogenase GLUT	Metabolic Disease Inflammation/Immunology Cancer
4'-Bromo-resveratrol (4′‐BR) is a dual SIRT1/SIRT3 inhibitor with an IC₅₀ of 0.2 mM for both targets. 4'-Bromo-resveratrol induces caspase-dependent apoptosis, induces G0/G1 cell cycle arrest, and inhiibits proliferation. 4'-Bromo-resveratrol reduces lactate production, glucose uptake, and NAD ⁺/NADH ratio, and downregulates lactate dehydrogenase A and glucose transporter 1 (GLUT1). 4'-Bromo-resveratrol can be used for the research of melanoma .

HY-B2227BS3

L-Lactic acid-13C-1 sodium (20% w/w in water) L-E-270-13C-1 sodium	Isotope-Labeled Compounds Bacterial Drug Intermediate Endogenous Metabolite	Infection Cancer
L-Lactic acid- ¹³C₁ (L-E-270- ¹³C₁) sodium (20% in water) is the ¹³C-labeled L-Lactic acid sodium (HY-W040233). L-lactate Sodium is a buildiing block which can be used as a precursor for the production of the bioplastic polymer poly-lactic acid. L-Lactic acid Sodium has antiproliferative activityy .

HY-152670

JC2-11 1 Publications Verification	NOD-like Receptor (NLR) AIM2	Inflammation/Immunology
JC2-11 is an inhibitor of inflammatory corpuscles. JC2-11 inhibits domain-containing protein NLRC 4, absent in melanoma 2 (AIM 2) and non-canonical (NC) inflammatory corpuscles. JC2-11 reduces the secretion of caspase-1 (p20), the cleavage of gasdermin D (GSDMD), and the releases of IL-1β and lactate dehydrogenases (LDH) in inflammatory bodies. JC2-11 inhibits the activation of inflammatory bodies by destroying the production of reactive oxygen species and the activity of caspase-1 .

HY-124309

NHI-2	Lactate Dehydrogenase Apoptosis	Cancer
NHI-2 is a lactate dehydrogenase A (LDHA) inhibitor with an IC₅₀ of 14.7 µM. NHI-2 shows selective for LDHA over LDHB (IC₅₀ = 55.8 µM). NHI-2 is an efficient anti-glycolytic agent. NHI-2 enhances apoptosis, induces cell cycle arrest at S and G2 phases. NHI-2 has a broad spectrum anti-proliferative activity in cancer cells. NHI-2 affects extracellular acidification rate and ATP production. NHI-2 suppresses tumor growth in murine B78 melanoma tumor model .

HY-Y0479AS2

L-Lactate-13C sodium (20% in water) 1 Publications Verification (S)-2-Hydroxypropanoic acid-13C sodium	Isotope-Labeled Compounds Drug Intermediate Antibiotic Bacterial Endogenous Metabolite	Infection Cancer
L-Lactate- ¹³C ((S)-2-Hydroxypropanoic acid- ¹³C) sodium is the ¹³C-labeled L-Lactic acid sodium (HY-W040233). L-lactate Sodium is a buildiing block which can be used as a precursor for the production of the bioplastic polymer poly-lactic acid. L-Lactic acid Sodium has antiproliferative activity .

HY-156683

CHK-336	Lactate Dehydrogenase	Metabolic Disease
CHK-336 (Example 1) is an orally active LDHA inhibitor (IC₅₀<1 nM). CHK-336 inhibits lactate production in mouse hepatocytes. CHK-336 can be used in the study of hyperoxaluria .

HY-N10574A

Queuine dihydrochloride 1 Publications Verification	Others	Metabolic Disease Cancer
Queuine dihydrochloride is a selective substrate for tRNA guanine transglycosylase (TGT) and can be incorporated into eukaryotic tRNA. Queuine dihydrochloride promotes tRNA modification, affecting mitochondrial function and Warburg metabolic phenotype. If Queuine dihydrochloride is deficient, aerobic glycolysis can be enhanced, oxidative phosphorylation can be inhibited, and Warburg metabolism can be promoted, accompanied by increased ammonia and lactate production and increased lactate dehydrogenase activity. Queuine dihydrochloride can be used for autoimmune diseases (such as experimental models of multiple sclerosis) and cancer metabolic regulation, and its deficiency is associated with low tRNA modification in tumor cells .

HY-176798

NCI-006	Lactate Dehydrogenase Reactive Oxygen Species (ROS) Apoptosis	Cancer
NCI-006 is an orally active lactate dehydrogenase (LDH) inhibitor (LDHA IC₅₀ = 0.06 μM; LDHB IC₅₀ = 0.03 μM). NCI-006 inhibits intratumoral LDH activity, lactate production, and tumor growth in a mouse pancreatic cancer model. NCI-006 inhibits glycolysis and induces apoptosis in vitro. NCI-006 enhances the radiosensitivity of glycolytic tumor cell lines while sparing non-glycolytic/normal cells (1522, skin fibroblasts) in combination with ionizing radiation (IR). NCI-006 exhibits synergistic antitumor effects in combination with IACS-010759 (HY-112037) against colorectal and gastric cancers. NCI-006 targets glycolysis by inhibiting lactate dehydrogenase impairs tumor growth in an Ewing sarcoma model .

HY-W040233R

L-Lactic acid sodium (Standard) (S)-2-Hydroxypropanoic acid sodium (Standard)	Bacterial Reference Standards	Infection Cancer
Sodium (S)-2-hydroxypropanoate (Standard) is the analytical standard of Sodium (S)-2-hydroxypropanoate. This product is intended for research and analytical applications. L-lactate Sodium (Sodium (S)-2-hydroxypropanoate) is a buildiing block which can be used as a precursor for the production of the bioplastic polymer poly-lactic acid. L-Lactic acid Sodium has antiproliferative activity .

HY-178761

PGK1-IN-1	Phosphoglycerate Kinase (PGK) Keap1-Nrf2 Heme Oxygenase (HO) Interleukin Related	Inflammation/Immunology
PGK1-IN-1 (Compound 6e) is a potent and selective PGK1 inhibitor (IC₅₀: 33 nM). PGK1-IN-1 inhibits PGK1-mediated glycolytic metabolism and reduces glucose consumption/lactate production. PGK1-IN-1 enhances Nrf2 accumulation and HO-1 expression, and suppresses the transcription and protein levels of the inflammatory cytokines IL-1β and IL-6. PGK1-IN-1 ameliorates Dextran sulfate sodium (DSS) (HY-116282C)-induced experimental colitis in mice. PGK1-IN-1 can be used for research of inflammatory bowel disease (IBD) .

HY-W039898

α-D-Mannose pentaacetate 1,2,3,4,6-Penta-O-acetyl-α-D-mannopyranose	Biochemical Assay Reagents Lactate Dehydrogenase	Metabolic Disease
α-D-Mannose pentaacetate (1,2,3,4,6-Penta-O-acetyl-α-D-mannopyranose) acts as a lactate promoter. It increases lactate production in rat red blood cells .

HY-N8540

Ilicicolin H	Phosphoglycerate Kinase (PGK) Fungal Apoptosis	Infection Cancer
Ilicicolin H is a selective and non-ATP-competitive phosphoglycerate kinase 1 (PGK1) (IC₅₀ = 9.02 μM) and mitochondrial cytochrome bc1 reductase (IC₅₀ = 2-3 ng/mL) inhibitor. Ilicicolin H directly binds to PGK1 with K_D of 60 μM .Ilicicolin H can inhibit cell proliferation and induce apoptosis. Ilicicolin H can inhibit the lactate production and glucose uptake of hepatocellular carcinoma (HCC) cells. Ilicicolin H has a broad antifungal spectrum including C. albicans, Cryptococcus and A. fumigatus. Ilicicolin H can be used for the researches of cancer and infection, such as hepatocellular carcinoma (HCC) and C. albicans infection .

HY-W040298

Ciprofloxacin lactate Bay-09867 lactate	Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species (ROS)	Infection Cancer
Ciprofloxacin (Bay-09867) lactate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin lactate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin lactate has anti-proliferative activity and induces apoptosis. Ciprofloxacin lactate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity .

HY-175230

ZG-2492	Lactate Dehydrogenase Apoptosis	Cancer
ZG-2492 is an orally active LDHA inhibitor with an IC₅₀ of 156 nM. ZG-2492 can reduce lactate production and induce cell cycle arrest and apoptosis in pancreatic cancer cells . ZG-2492 has antitumor activity and can be used in the research of tumors such as pancreatic cancer .

HY-151243

NCATS-SM1441	Lactate Dehydrogenase	Cancer
NCATS-SM1441 (compound 52) is a lactate dehydrogenase (LDH) inhibitor (IC₅₀=40 nM). By inhibiting the activity of LDH, NCATS-SM1441 is able to reduce the production of lactic acid in cancer cells, helping to slow or stop the proliferation of cancer cells. NCATS-SM1441 can be used to study cancer metabolism .

HY-W040298R

Ciprofloxacin lactate (Standard) Bay-09867 lactate (Standard)	Reference Standards Topoisomerase Apoptosis Antibiotic Bacterial Mitochondrial Metabolism Reactive Oxygen Species (ROS)	Infection Cancer
Ciprofloxacin (lactate) (Standard) is the analytical standard of Ciprofloxacin (lactate). This product is intended for research and analytical applications. Ciprofloxacin (Bay-09867) lactate is a potent, orally active topoisomerase IV inhibitor. Ciprofloxacin lactate induces mitochondrial DNA and nuclear DNA damage and lead to mitochondrial dysfunction, ROS production. Ciprofloxacin lactate has anti-proliferative activity and induces apoptosis. Ciprofloxacin lactate is a fluoroquinolone antibiotic, exhibiting potent antibacterial activity [4].

HY-178461

LDHA-IN-10	Lactate Dehydrogenase	Cancer
LDHA-IN-10 (Compound HP19) is a Lactate Dehydrogenase-A (LDHA) inhibitor with an IC₅₀ value of 5.2 μM. LDHA-IN-10 reduces lactate production and ATP levels, inhibiting the proliferation of pancreatic cancer cell line PANC-1. LDHA-IN-10 induces G1/S cell cycle arrest and promotes apoptosis. LDHA-IN-10 is promising for research of pancreatic ductal adenocarcinoma (PDAC) .

HY-162831

MPC-IN-1	Mitochondrial Metabolism	Others
MPC-IN-1 (compound 4i) is a cyanocinnamate-based, mitochondrial pyruvate transporter (MPC) inhibitor, and is a derivative of UK-5099 (HY-15475). MPC inhibitors promote the development of hair follicle stem cells without affecting normal cells. MPC-IN-1 promotes cellular lactate production and promotes significant hair growth in mice, and has the potential to be used to inhibit hair loss .

HY-179027

LDH-IN-5	Lactate Dehydrogenase Apoptosis Reactive Oxygen Species (ROS) SOD	Neurological Disease
LDH-IN-5 is a Lactate Dehydrogenase (LDH) inhibitor with neuroprotective activity. LDH-IN-5 can inhibit cell apoptosis, reduce ROS, MDA production and increases superoxide dismutase (SOD) activity. LDH-IN-5 can be used for the research of neurological disease, such as ischemic stroke .

HY-N1511R

Ganoderic acid D (Standard)	Reference Standards Sirtuin Apoptosis	Cancer
Ganoderic acid D (Standard) is the analytical standard of Ganoderic acid D. This product is intended for research and analytical applications. Ganoderic acid D, a highly oxygenated tetracyclic triterpenoid, is the major active component of Ganoderma lucidum. Ganoderic acid D upregulates the protein expression of SIRT3 and induces the deacetylated cyclophilin D (CypD) by SIRT3. Ganoderic acid D inhibits the energy reprogramming of colon cancer cells including glucose uptake, lactate production, pyruvate and acetyl-coenzyme production in colon cancer cells . Ganoderic acid D induces HeLa human cervical carcinoma apoptosis .

HY-113853

WF-10129	Akt Apoptosis	Others
WF-10129 is a cytotoxic steroidal compound isolated from the plant Physalis. WF-10129 inhibits liver cancer cell proliferation, induces apoptosis, interferes with metabolism, and significantly reduces lactate production in vitro and in vivo. WF-10129 can also exert anti-tumor activity by regulating the expression of related genes and proteins through the AKT-p53 pathway.

HY-157992

LM-021	Interleukin Related Caspase Lactate Dehydrogenase Reactive Oxygen Species (ROS)	Neurological Disease Inflammation/Immunology
LM-021 is a coumarin-chalcone derivative with anti-aggregatory, antioxidant, neuroprotective and anti-inflammatory properties which suppresses nitric oxide (NO), IL-1β, IL-6, TNF-α production, CD68 antigen (CD68) and histocompatibility-2 (MHCII) expression. LM-021 also attenuates the increase of caspase 1 activity, lactate dehydrogenase release and ROS level. LM-021 can be used for neurological research .

HY-181267

ALDOA-IN-1	Fructose-1,6-bisphosphate aldolase HIF/HIF Prolyl-Hydroxylase Apoptosis	Cancer
ALDOA-IN-1 is an aldolase A(ALDOA) inhibitor. ALDOA-IN-1 directly inhibits ALDOA enzymatic activity, thereby reducing lactate production, downregulating HIF-1α expression, and ultimately inducing cancer cell apoptosis. ALDOA-IN-1 can be used for research on colorectal cancer .

HY-W698271

Ferrous lactate trihydrate	Biochemical Assay Reagents	Metabolic Disease
Ferrous lactate trihydrate is a type of iron supplement. Ferrous lactate trihydrate promotes the production of hemoglobin by providing available ferrous ions (Fe²⁺). Ferrous lactate trihydrate can be used in studies on iron-deficiency anemia .

HY-183858

NCATS-SM1440	Lactate Dehydrogenase	Cancer
NCATS-SM1440 is a glycolysis inhibitor and metabolic regulator that targets LDHA and LDHB (IC₅₀=0.06 μM and 0.03 μM, respectively). Upon binding to LDHA, NCATS-SM1440 blocks the glycolysis pathway and reduces lactate production. NCATS-SM1440 drives the shift of pyruvate metabolism toward mitochondrial metabolism, effectively disrupting the dependence of cancer cells on aerobic glycolysis. NCATS-SM1440 can be widely used in research related to cancer, Ewing's sarcoma, and other related conditions .

HY-118241

GNE-140	Lactate Dehydrogenase Bacterial Apoptosis Reactive Oxygen Species (ROS)	Cardiovascular Disease Infection Inflammation/Immunology Cancer
GNE-140 is an orally active and selective inhibitor of lactate dehydrogenase (LDH) A, B and C, with IC₅₀ values of 3, 5 and 5 nM against LDHA, LDHB, LDHC, respectively. GNE-140 blocks the conversion of pyruvate to lactate, reduces lactate production and histone lysine lactylation, and inhibits glycolysis. GNE-140 attenuates cardiac hypertrophy, alleviates PM_2.5-induced pulmonary inflammation and fibrosis, blocks MRSA-induced Arg1 expression, regulates metabolites of glycolysis and the pentose phosphate pathway, reduces glucose uptake, increases ROS, and induces cancer cell apoptosis. GNE-140 is applicable to research related to pathological cardiac hypertrophy, pulmonary fibrosis, MRSA infection and pancreatic cancer .

HY-181677

Antibacterial agent 325	Bacterial Reactive Oxygen Species (ROS) Lactate Dehydrogenase	Infection
Antibacterial agent 325 is an antibacterial agent. Antibacterial agent 325 exerts potent broad-spectrum antibacterial activity and shows bactericidal activity. Antibacterial agent induces membrane depolarization, disrupts the membrane integrity, increasess ROS production and lipid peroxidation levels. Antibacterial agent 325 inhibits the metabolic activity and Lactate Dehydrogenase (LDH) activity. Antibacterial agent 325 exhibits low drug resistance development in bacteria, low hemolysis and cytotoxicity. Antibacterial agent 325 can be used for the research of bacterial infection .

HY-183148

NAMPT activator-10	NAMPT ATP Synthase	Neurological Disease
NAMPT activator-10 (Compound B11) is an orally active NAMPT activator with a target K_d value of 0.64 μM. NAMPT activator-10 activates the rate-limiting enzyme in NAD ⁺ biosynthesis and promotes intracellular NAD ⁺ synthesis. NAMPT activator-10 reduces lactate accumulation, enhances glycogen storage in the liver and muscle, increases tissue ATP production, improves exercise endurance and muscle strength, and exerts a protective effect against fatigue-induced muscle damage in mouse fatigue models. NAMPT activator-10 can be used in studies related to muscle fatigue .

HY-182469

FuBIG	Lactate Dehydrogenase AMPK FOXO Interleukin Related Reactive Oxygen Species (ROS) TNF Receptor Bcl-2 Family Caspase Apoptosis	Neurological Disease
FuBIG is an iminoguanidine derivative with neuroprotective effects. FuBIGL inhibits L-LDH activation and reduces lactate production. FuBIGL exerts protective effects on inflammatory nerve cells, upregulates the expressions of AMPK, pAMPK and FOXO3, and activates the AMPK pathway in cells. FuBIG exerts anti-inflammatory effects by reducing pro-inflammatory cytokines (IL-6, IL-1β, TNF-α) and increasing the anti-inflammatory cytokine IL-10. FuBIG maintains mitochondrial membrane potential, alleviates mitochondrial dysfunction, reduces ROS production, and relieves oxidative stress. FuBIG upregulates Bcl-2, downregulates Bax and Caspase-3, and inhibits cell apoptosis (apoptosis). FuBIG improves metabolic disorders in diabetic mice, decreases the levels of LDL-C, ALT and AST, and increases HDL-C level simultaneously. FuBIG can be used in the research of diabetic neuroinflammation .

HY-182243

HK2-IN-4	Hexokinase VDAC Apoptosis AMPK Bcl-2 Family	Cancer
HK2-IN-4 is a selective hexokinase 2 (HK2) inhibitor with an IC₅₀ value of 0.79 μM and a K_d value of 0.41 μM. HK2-IN-4 blocks the interaction between HK2 and voltage-dependent anion channel 1 (VDAC1). HK2-IN-4 reduces lactate and ATP levels in cancer cells. HK2-IN-4 induces the production of apoptosis (apoptosis) markers in cancer cells, including increased p-AMPK/AMPK ratio and Bax levels, as well as decreased Bcl2 levels. HK2-IN-4 inhibits the proliferation of cancer cells with high HK2 expression. HK2-IN-4 can be used in research related to colorectal cancer and non-small cell lung cancer .

Cat. No.	Product Name

HY-L250

Lactic Acid Metabolite Compound Library	63 compounds
In the progression of various diseases, metabolic reprogramming has emerged as a key hallmark. Lactate, as an important metabolic signaling molecule, is widely involved in tumorigenesis, immune regulation, and inflammatory responses. Particularly within the tumor microenvironment, the abnormal accumulation of lactate not only affects cellular energy metabolism but also promotes disease progression by modulating immune cell functions and mediating protein lactylation, thereby participating in epigenetic regulation and signaling networks. Therefore, systematic investigation of lactate metabolic pathways and their associated metabolites is of great significance for understanding disease mechanisms and developing novel therapeutic strategies. The MCE lactic acid metabolite compound library contains 63 compounds and is constructed around key metabolic pathways involving lactate production, transport, and utilization. This library systematically includes core intermediates from glycolysis, the tricarboxylic acid (TCA) cycle, and the lactate cycle. Focusing on disease-associated metabolic reprogramming, it is suitable for research in oncology, inflammation, and metabolic disorders. The library can be used to elucidate the roles of lactate in tumor microenvironment regulation, immune evasion, and epigenetic modifications (such as protein lactylation). In addition, it provides high-quality small-molecule resources for drug screening, facilitating the discovery of potential modulators targeting key enzymes (such as LDH) or transporters (such as MCTs) involved in lactate metabolism.

Lactic Acid Metabolite Compound Library

63 compounds

In the progression of various diseases, metabolic reprogramming has emerged as a key hallmark. Lactate, as an important metabolic signaling molecule, is widely involved in tumorigenesis, immune regulation, and inflammatory responses. Particularly within the tumor microenvironment, the abnormal accumulation of lactate not only affects cellular energy metabolism but also promotes disease progression by modulating immune cell functions and mediating protein lactylation, thereby participating in epigenetic regulation and signaling networks. Therefore, systematic investigation of lactate metabolic pathways and their associated metabolites is of great significance for understanding disease mechanisms and developing novel therapeutic strategies.

The MCE lactic acid metabolite compound library contains 63 compounds and is constructed around key metabolic pathways involving lactate production, transport, and utilization. This library systematically includes core intermediates from glycolysis, the tricarboxylic acid (TCA) cycle, and the lactate cycle. Focusing on disease-associated metabolic reprogramming, it is suitable for research in oncology, inflammation, and metabolic disorders. The library can be used to elucidate the roles of lactate in tumor microenvironment regulation, immune evasion, and epigenetic modifications (such as protein lactylation). In addition, it provides high-quality small-molecule resources for drug screening, facilitating the discovery of potential modulators targeting key enzymes (such as LDH) or transporters (such as MCTs) involved in lactate metabolism.

HY-L204

Lactic Acid Metabolic Compound Library	535 compounds
Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism. MCE contains 535 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.

Lactic Acid Metabolic Compound Library

535 compounds

Lactic acid metabolism is one of the key metabolic pathways within living organisms. It plays a crucial role not only in cellular energy conversion but is also closely related to a variety of physiological and pathological processes. The production and clearance of lactic acid are important indicators of cellular metabolic balance, and its abnormal regulation may lead to conditions such as lactic acidosis, muscle fatigue, and hereditary metabolic diseases. Moreover, lactic acid is closely related to the malignancy of tumors and is considered a biomarker for malignant tumors and poor prognosis. Lactic acid can serve as a metabolic substrate to support the metabolic needs of tumor cells under hypoxic conditions, and it can also cause acidification of the tumor microenvironment, suppress immune cell function to promote immune evasion, and induce drug resistance in tumor cells. Currently, targeting lactic acid-lactylation and its related metabolic pathways has become a new research avenue for cancer treatment. In-depth exploration of the molecular mechanisms of lactic acid metabolism can help in screening lead compounds that regulate the lactic acid metabolism.

MCE contains 535 small molecule compounds targeting enzymes involved in lactic acid metabolism. This library is of significant value for researching the role of lactate metabolism in the mechanisms of diseases.

α-D-Mannose pentaacetate 1,2,3,4,6-Penta-O-acetyl-α-D-mannopyranose	Biochemical Assay Reagents
α-D-Mannose pentaacetate (1,2,3,4,6-Penta-O-acetyl-α-D-mannopyranose) acts as a lactate promoter. It increases lactate production in rat red blood cells .

Cat. No.	Product Name	Category	Target	Chemical Structure